PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
26.51%
Positive growth while VET shows revenue decline. John Neff would investigate competitive advantages.
55.07%
Cost increase while VET reduces costs. John Neff would investigate competitive disadvantage.
4.70%
Gross profit growth exceeding 1.5x VET's 0.33%. David Dodd would verify competitive advantages.
-17.24%
Margin decline while VET shows 4.99% expansion. Joel Greenblatt would examine competitive position.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
10.81%
Other expenses growth less than half of VET's 92.40%. David Dodd would verify if advantage is sustainable.
11.04%
Operating expenses growth while VET reduces costs. John Neff would investigate differences.
39.69%
Total costs growth while VET reduces costs. John Neff would investigate differences.
No Data
No Data available this quarter, please select a different quarter.
10.34%
D&A growth while VET reduces D&A. John Neff would investigate differences.
3.96%
EBITDA growth 1.25-1.5x VET's 2.70%. Bruce Berkowitz would examine sustainability.
-16.82%
EBITDA margin decline while VET shows 7.48% growth. Joel Greenblatt would examine position.
32.40%
Operating income growth exceeding 1.5x VET's 6.29%. David Dodd would verify competitive advantages.
4.65%
Operating margin growth below 50% of VET's 11.23%. Michael Burry would check for structural issues.
-7178.76%
Other expenses reduction while VET shows 68.78% growth. Joel Greenblatt would examine advantage.
-32.52%
Pre-tax income decline while VET shows 65.08% growth. Joel Greenblatt would examine position.
-46.66%
Pre-tax margin decline while VET shows 72.75% growth. Joel Greenblatt would examine position.
-50.22%
Tax expense reduction while VET shows 46.72% growth. Joel Greenblatt would examine advantage.
-24.51%
Net income decline while VET shows 78.07% growth. Joel Greenblatt would examine position.
-40.33%
Net margin decline while VET shows 86.34% growth. Joel Greenblatt would examine position.
-10.71%
EPS decline while VET shows 77.78% growth. Joel Greenblatt would examine position.
-12.09%
Diluted EPS decline while VET shows 95.83% growth. Joel Greenblatt would examine position.
-1.87%
Share count reduction while VET shows 0.00% change. Joel Greenblatt would examine strategy.
-0.44%
Diluted share reduction while VET shows 0.00% change. Joel Greenblatt would examine strategy.